Even today, racist perspectives can be proposed on religious grounds--e.g., "In his controversial book, Who Are Wei, Samuel Huntington called on Congress to adopt immigration criteria aimed at preserving the so-called 'Anglo-Protestant culture'" (Liav
Orgad and Theodore Ruthizer, "Race, Religion, and Nationality in Immigration Selection: 120 Years after the Chinese Exclusion Case," Constitutional Commentary 26 [Spring, 2010]: 261).
(84.) See generally SHLOMO AVINERI, LIAV
ORGAD & AMNON RUBINSTEIN, MANAGING GLOBAL MIGRATION: A STRATEGY FOR ISRAELI IMMIGRATION POLICY (Ruth Gavison ed., 2010).
Those who see the paralytic take up his bed and walk experience an ecstatic joy that makes them glorify God (hoste existasthai pantas kai doxazein theon, 2:12); those who witness the raising up of the little girl go out of their minds with ecstasy (kai exestesan ekstasei megale, 5:42); the disciples who watch Jesus walk on the water and then quiet the wind are "utterly [and beyond measure] beside themselves" (kai liav
[ek perissou] ev eautois existanto, 6:51).
Endo (ENDP), down 4% after Citi analyst Liav
Abraham downgraded shares to Neutral from Buy.
(53) See Handler et al., supra note 47, at 122-23 ("The Jacobson court's unequivocal rejection of the preamble as a source of rights has effectively discouraged most courts from considering the preamble in any context in which any contentious issues arise concerning liberty, justice or welfare."); see also Liav
Orgad, The Preamble in Constitutional Interpretation, 8 INT'L J.
Alkermes (ALKS) downgraded to Neutral from Buy at Citi with analyst Liav
Abraham saying while the positive Phase 3 data for ALKS 3831 in Q4 support a constructive view on the compound, there are not "sufficient meaningful catalysts to drive material upside" in the stock for the remainder of 2019.
Citi analyst Liav
Abraham downgraded Alkermes to Neutral from Buy and cut her price target for the shares to $33 from $62.
Horizon Pharma (HZNP) downgraded to Neutral from Buy at Citi with analyst Liav
Abraham saying he sees limited upside to valuation at current levels following the recent upward inflection in the share price.
Citi analyst Liav
Abraham says that while Alkermes' (ALKS) fiscal 2018 revenue outlook came in below expectations, catalysts are the "major force this year." The analyst expects data from two of the company's pivotal programs and clarity around the regulatory pathway for ALKS 5461.
The FDA's supportive stance of DBV Technologies' submission of a Biologics License Application for Viaskin Peanut is a positive of the stock, Citi analyst Liav
Abraham tells investors in a research note.